E Fund Management Co. Ltd. Buys New Position in ArriVent BioPharma, Inc. $AVBP

E Fund Management Co. Ltd. acquired a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 109,328 shares of the company’s stock, valued at approximately $3,798,000.

Several other institutional investors have also added to or reduced their stakes in AVBP. Russell Investments Group Ltd. grew its stake in ArriVent BioPharma by 9,747.6% in the third quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company’s stock worth $38,000 after purchasing an additional 2,047 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in ArriVent BioPharma by 27.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company’s stock valued at $40,000 after buying an additional 438 shares during the period. BNP Paribas Financial Markets lifted its position in ArriVent BioPharma by 31.0% during the second quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock valued at $56,000 after buying an additional 609 shares during the period. Group One Trading LLC bought a new stake in shares of ArriVent BioPharma during the 4th quarter valued at $57,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of ArriVent BioPharma by 696.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,258 shares of the company’s stock worth $60,000 after buying an additional 2,849 shares during the period. 9.48% of the stock is currently owned by institutional investors.

More ArriVent BioPharma News

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $47 price target for ArriVent BioPharma (AVBP), indicating confidence in the company’s long-term potential and significant potential upside. HC Wainwright Forecasts Strong Price Appreciation for ArriVent BioPharma Stock
• Neutral Sentiment: HC Wainwright expects continued losses through 2027, forecasting EPS of approximately ($1.11) in the first quarter, ($1.16) in the second quarter, ($1.04) in the third quarter and ($0.93) in the fourth quarter of 2027. The estimates suggest profitability remains several quarters away.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS forecast to ($1.04) from ($0.96), its Q4 2026 forecast to ($1.07) from ($0.99), and its full-year 2026 forecast to ($4.14) from ($3.86). The downward revisions indicate analysts expect heavier losses than previously projected.

ArriVent BioPharma Price Performance

AVBP stock opened at $30.02 on Thursday. ArriVent BioPharma, Inc. has a 1-year low of $17.00 and a 1-year high of $35.83. The business has a fifty day moving average price of $31.74 and a 200-day moving average price of $28.00. The stock has a market capitalization of $1.48 billion, a P/E ratio of -8.29 and a beta of 1.36.

ArriVent BioPharma (NASDAQ:AVBP) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.06). As a group, analysts anticipate that ArriVent BioPharma, Inc. will post -4.01 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Guggenheim reaffirmed a “buy” rating and set a $45.00 target price on shares of ArriVent BioPharma in a research note on Thursday, August 13th. HC Wainwright upped their price target on ArriVent BioPharma from $44.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday. BTIG Research reaffirmed a “buy” rating and set a $42.00 price objective on shares of ArriVent BioPharma in a research report on Thursday, August 13th. Truist Financial lifted their price target on ArriVent BioPharma from $43.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, May 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Friday, July 17th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $44.86.

ArriVent BioPharma Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.